PL370589A1 - Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases - Google Patents

Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Info

Publication number
PL370589A1
PL370589A1 PL02370589A PL37058902A PL370589A1 PL 370589 A1 PL370589 A1 PL 370589A1 PL 02370589 A PL02370589 A PL 02370589A PL 37058902 A PL37058902 A PL 37058902A PL 370589 A1 PL370589 A1 PL 370589A1
Authority
PL
Poland
Prior art keywords
prophylaxis
cardiac
treatment
pharmaceutical composition
controlled release
Prior art date
Application number
PL02370589A
Other languages
English (en)
Polish (pl)
Inventor
Dilip Shantilal Shanghvi
Bala Ramesha R. Chary
Ziauddin Z. Tyebji
Original Assignee
Sun Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd. filed Critical Sun Pharmaceutical Industries Ltd.
Publication of PL370589A1 publication Critical patent/PL370589A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
PL02370589A 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases PL370589A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (en:Method) 2001-05-17 2001-05-17

Publications (1)

Publication Number Publication Date
PL370589A1 true PL370589A1 (en) 2005-05-30

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370589A PL370589A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Country Status (16)

Country Link
US (1) US20030035836A1 (en:Method)
EP (1) EP1395258A1 (en:Method)
JP (1) JP2004534031A (en:Method)
KR (1) KR20040037026A (en:Method)
CN (1) CN1525855A (en:Method)
AU (1) AU2002314515B2 (en:Method)
BE (1) BE1014328A7 (en:Method)
BR (1) BR0210976A (en:Method)
CA (1) CA2447005A1 (en:Method)
HU (1) HUP0400607A3 (en:Method)
IN (1) IN191028B (en:Method)
MX (1) MXPA03010501A (en:Method)
PL (1) PL370589A1 (en:Method)
RU (1) RU2003133446A (en:Method)
WO (1) WO2002092078A1 (en:Method)
ZA (1) ZA200309724B (en:Method)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327685C (en) 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
JP2005533823A (ja) 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
US20050261355A1 (en) 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
EP2301526B1 (en) 2003-03-26 2016-03-23 Egalet Ltd. Morphine controlled release system
DE602004014747D1 (de) 2003-03-26 2008-08-14 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
ES2737348T3 (es) * 2003-09-12 2020-01-13 Amgen Inc Formulación de disolución rápida que comprende cinacalcet HCl
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
US7750036B2 (en) 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US20080076743A1 (en) 2006-08-03 2008-03-27 Nitec Pharma Ag Delayed-Release Glucocorticoid treatment of Rheumatoid Disease
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
ES2600894T3 (es) * 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014034929A1 (ja) 2012-09-03 2014-03-06 第一三共株式会社 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CN1251987A (zh) * 1997-03-11 2000-05-03 达尔文发现有限公司 含有r－和s－对映体分离部分的剂型
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6515010B1 (en) * 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
EP1272180B1 (en) * 2000-04-03 2004-09-29 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
JP2004518734A (ja) * 2000-10-24 2004-06-24 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規処方

Also Published As

Publication number Publication date
EP1395258A1 (en) 2004-03-10
CN1525855A (zh) 2004-09-01
JP2004534031A (ja) 2004-11-11
ZA200309724B (en) 2005-05-25
KR20040037026A (ko) 2004-05-04
AU2002314515B2 (en) 2007-08-16
HUP0400607A2 (hu) 2004-07-28
IN191028B (en:Method) 2003-09-13
US20030035836A1 (en) 2003-02-20
BE1014328A7 (fr) 2003-08-05
RU2003133446A (ru) 2005-03-10
MXPA03010501A (es) 2004-03-02
CA2447005A1 (en) 2002-11-21
BR0210976A (pt) 2004-10-05
HUP0400607A3 (en) 2005-07-28
WO2002092078A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
HUP0400607A3 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
IL151689A0 (en) Intracorporeal medicaments for photodynamic treatment of disease
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
AU7434101A (en) Treatment of bone diseases
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
EP1536834A4 (en) DESIGN OF CHEMOKINE ANALOGS FOR THE TREATMENT OF HUMAN DISEASES
GB0514417D0 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2003271021A8 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
GB0004531D0 (en) The treatment of respiratory diseases
AU2001253125A1 (en) Intracorporeal medicaments for high energy phototherapeutic treatment of disease
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)